177Lu-PSMA治疗联合帕博利珠单抗或奥拉帕利预处理的首例经验
本文报告2例转移性去势抵抗性前列腺癌患者,在常规治疗耗尽或不适合后接受177Lu-PSMA放射性配体治疗:1例同时使用帕博利珠单抗治疗皮肤鳞状细胞癌,另1例在奥拉帕利单药治疗3个月后序贯接受放射性配体治疗。两例均未出现显著血液毒性,例2获影像学和生化反应,例1在3个周期后前列腺特异性抗原稳定。提示联合或序贯方案在个别患者中可能耐受良好。
要点
- 177Lu-PSMA联合帕博利珠单抗或奥拉帕利后序贯治疗在2例患者中耐受良好。
- 例2在奥拉帕利单药3个月后序贯放射性配体治疗获影像学和生化反应。
- 例1联合帕博利珠单抗治疗3个周期后前列腺特异性抗原稳定。
核心结论
- 这些病例提示177Lu-PSMA放射性配体治疗联合帕博利珠单抗或奥拉帕利序贯治疗在个别患者中可能耐受良好。
研究设计与样本
- 本文报告2例接受联合或序贯治疗的转移性去势抵抗性前列腺癌患者。
- 放射性配体治疗在患者耗尽或不适合所有已批准常规治疗后以6至8周间隔进行。
- 例1同时因皮肤鳞状细胞癌使用帕博利珠单抗,例2在奥拉帕利单药治疗3个月后4周序贯接受放射性配体治疗。
主要发现
- 两例患者均耐受放射性配体治疗,未出现任何显著血液毒性。
- 例2显示影像学和生化反应。
- 例1在3个治疗周期后达到前列腺特异性抗原稳定。
临床怎么用
- 在常规治疗耗尽或不适合的转移性去势抵抗性前列腺癌个别患者中,可考虑177Lu-PSMA放射性配体治疗联合帕博利珠单抗或奥拉帕利序贯治疗并监测血液毒性。
局限性
- 本文仅为2例个别患者的经验报告,证据有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Synergistic effects of immunotherapy with pembrolizumab or drugs targeting DNA damage, such as olaparib, might be used to overcome the limitations of radioligand therapy (RLT) with 177Lu-prostate-specific membrane antigen (PSMA) in metastasized castration-resistant prostate cancer. Here, we present 2 patients receiving such combination or sequential therapies. Methods: RLT was performed at 6- to 8-wk intervals after the patients either exhausted or were considered unfit for all approved conventional treatments. Patient 1 was on pembrolizumab for his squamous cell carcinoma of the skin, whereas patient 2 received RLT sequentially 4 wk after 3 mo of monotherapy with olaparib. Results: Both patients tolerated RLT without any significant hematotoxicity. Patient 2 showed a radiologic and biochemical response, whereas patient 1 achieved prostate-specific antigen stabilization after 3 therapy cycles. Conclusion: These cases indicate that RLT in combination with pembrolizumab or sequentially after olaparib might be well tolerated in single patients.
引用
- Prasad V, Zengerling F, Steinacker JP, et al. First Experiences with 177Lu-PSMA Therapy in Combination with Pembrolizumab or After Pretreatment with Olaparib in Single Patients. J Nucl Med. 2020. PMID: 33246977. doi:10.2967/jnumed.120.249029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。